MedTrace Logo

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke

NCT00790920 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 492

Last updated 2015-09-18

No results posted yet for this study

Summary

The purpose of the study is to determine whether desmoteplase is effective and safe in the treatment of patients with acute ischaemic stroke when given within 3-9 hours from onset of stroke symptoms.

Conditions

Interventions

DRUG

Desmoteplase

90 μg/kg bodyweight, IV, single bolus over 1 - 2 minutes on 1st day

DRUG

Placebo

IV, single bolus over 1 - 2 minutes on 1st day

Sponsors & Collaborators

  • H. Lundbeck A/S

    lead INDUSTRY

Principal Investigators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2014-07-31

Countries

  • Australia
  • Austria
  • Estonia
  • France
  • Germany
  • Hong Kong
  • India
  • Netherlands
  • Philippines
  • Poland
  • Singapore
  • South Korea
  • Spain
  • Switzerland
  • Taiwan
  • Thailand
  • Vietnam

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00790920 on ClinicalTrials.gov